Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. |
|||
|
|||
Medicine details |
|||
| Medicine name | saxagliptin (Onglyza®) | ||
| Formulation | 2.5 mg film-coated tablet, 5 mg film-coated tablet | ||
| Reference number | 1975 | ||
| Indication | In adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca UK Ltd | ||
| BNF chapter | Endocrine system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 3313 | ||
| NMG meeting date | 23/10/2013 | ||
| AWMSG meeting date | 20/11/2013 | ||
| Ratification by Welsh Government | 06/12/2013 | ||
| Date of issue | 13/12/2013 | ||
| Date of last review | 20/01/2017 | ||